[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646272":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":86,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Then NR","EXPERIMENTAL","Participants assigned to this arm will receive matched placebo for 12 weeks, followed by an approximately 14-day washout\u002Fcrossover period, then nicotinamide riboside 1000 mg\u002Fday for 12 weeks.",[13],"Dietary Supplement: Matched Placebo (Capsules)",{"label":15,"type":10,"description":16,"interventionNames":17},"NR Then Placebo","Participants assigned to this arm will receive nicotinamide riboside 1000 mg\u002Fday for 12 weeks, followed by an approximately 14-day washout\u002Fcrossover period, then matched placebo for 12 weeks.",[18],"Dietary Supplement: Nicotinamide Riboside (NR)",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Nicotinamide Riboside (NR)","Nicotinamide riboside will be administered orally at a target dose of 1000 mg\u002Fday for 12 weeks during the active treatment period.",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Matched Placebo (Capsules)","Matched placebo will be administered orally for 12 weeks during the placebo treatment period. The placebo will be identical or substantially similar in appearance to the active nicotinamide riboside study product to maintain blinding.",[9],[31],{"name":32,"affiliation":5,"role":33},"Armin Ahmadi, PhD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","619-543-6248","a3ahmadi@ucsd.edu",{"name":40,"role":36,"phone":25,"phoneExt":25,"email":41},"Rakesh Malhotra, MD, MPH","r3malhotra@health.ucsd.edu",[43],{"facility":44,"status":25,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Altman Clinical and Translation Research Institute","San Diego","California","92093","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-117.16472,32.71571,{"lat":54,"lon":53},[57],{"name":32,"role":36,"phone":58,"phoneExt":25,"email":38},"(619) 543-6248",{"type":33,"investigatorFullName":32,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Assistant Professor","100646272","phase-2-nicotinamide-riboside-supplementation-in-chronic-kidney-disease-100646272",false,"NCT07693543","Nicotinamide Riboside Supplementation in Chronic Kidney Disease","Pilot Randomized Crossover Trial of Nicotinamide Riboside in Chronic Kidney Disease (NR-CKD Trial)","NR-CKD","Inclusion Criteria:\n\n* Moderate chronic kidney disease not treated with dialysis, defined as eGFR 30-59 mL\u002Fmin\u002F1.73 m2 using the CKD-EPI equation.\n* Urine albumin-to-creatinine ratio (uACR) \\\u003C300 mg\u002Fg.\n* Able to provide informed consent.\n* Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment.\n* Willing and able to comply with study procedures, visits, and study product administration.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Expectation to start dialysis within 6 months.\n* Unable to walk unassisted from room to room.\n* Institutionalization or inability to consent.\n* End-stage liver disease with cirrhosis.\n* HIV.\n* Oxygen-dependent COPD.\n* Baseline systolic blood pressure \\>170 mmHg or diastolic blood pressure \\>100 mmHg.\n* Current participation in another interventional trial.\n* Use of immunosuppressive medications, including steroids or calcineurin inhibitors.\n* Malignancy requiring active treatment or currently under surveillance at the discretion of the investigator.\n* Hospitalization for myocardial infarction, unstable angina, cerebrovascular accident, or unstable cardiac chest pain within the prior 3 months.","ALL","30 Years",{"count":72,"type":73},30,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism.\n\nThe main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures. The study will also explore whether NR chloride affects markers of mitochondrial health, small blood vessel function, and physical function.\n\nParticipants will be randomly assigned to one of two treatment orders. One group will take NR first and placebo second. The other group will take placebo first and NR second. Placebo looks like NR but does not contain active NR. Each treatment period lasts 12 weeks, with an approximately 2-week washout period between treatments. Neither participants nor the study team will know which treatment participants are taking during each period.\n\nStudy visits will include blood and urine collection, physical function testing, and noninvasive tests of small blood vessel function. The study will enroll up to 36 adults with moderate chronic kidney disease at the University of California, San Diego.",[79],"Chronic Kidney Disease",[81,82,83,84,85],"Nicotinamide riboside","Chronic kidney disease","Microvascular function","Physical function","Cell-free mitochondrial DNA","NOT_YET_RECRUITING","2026-07-13",{"date":89,"type":90},"2026-07-15","ACTUAL",{"date":92,"type":73},"2026-10-01",{"date":94,"type":73},"2028-09-30",{"name":5,"class":6},1]